Olympus Corporation of the Americas recalled the Bronchovideoscope BF-1TQ170 on September 11, 2025. The recall affects 2,092 units distributed outside the U.S. Additional instructions for safe use with laser and other therapies prompted this action.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The Bronchovideoscope BF-1TQ170 is subject to a recall due to updated instructions for use. The device is distributed nationwide in the U.S. and internationally. Specific model numbers include BF-1TQ170 and UDI: 4953170342943.
The recall addresses additional instructions for safe and effective use of the bronchovideoscope when combined with laser, argon plasma coagulation, and high-frequency therapy equipment. The updates clarify potential risks associated with the device's use.
There are no reported injuries or incidents associated with this recall. The device is classified as Class I, indicating a high hazard level.
Patients and healthcare providers should stop using the Bronchovideoscope BF-1TQ170 immediately. Follow the recall instructions provided by Olympus. Contact Olympus Corporation of the Americas or your healthcare provider for further instructions.
For more information, contact Olympus Corporation of the Americas at the provided link. For detailed recall instructions, visit the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.